Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery

Innoblative Designs

Status: Not yet enrolling

Conditions: Breast Cancer; ER/PR+Her2neu; Breast Cancer - Infiltrating Ductal Carcinoma; Breast-conserving Surgery; Grade I, II, III

Treatments: Device: Radiofrequency ablation alone; Device: Radiofrequency ablation Electrosurgical Device

Study type: Interventional

Funder types: Industry

Identifiers

NCT07206121

28001-CSP

Details and patient eligibility

About

This study aims to assess the safety and clinical accuracy of the SIRA-1000, SIRA® RFA Electrosurgical Device in ablating margins post-lumpectomy in patients undergoing breast conserving surgery for breast cancer. Radiofrequency ablation, or RFA, uses radio waves to create heat, that in turn, causes deliberate controlled damage to the tissue surrounding where the tumor was located. You may hear your doctor refer to this as the 'margins'. Your doctor is using this treatment to help destroy remaining cancer cells in the margins around the site of the lump.

Full description

During your surgery, after your lump is removed, the surgeon will place the SIRA-1000 in the breast cavity and perform the RF ablation procedure to treat the margins of the lumpectomy surgical site. A stitch will be used to stabilize and secure the tissue around the neck of the SIRA-1000 to ensure that contact is maintained between the SIRA-1000 electrode array and cavity tissue.

Upon completion of the RF ablation treatment, your tumor and the tissue samples from the ablated edges of the surgical site will be sent for review under a microscope (pathology).

After this, your surgery will be completed as standard, and your discharge will be determined by your medical team like any other surgery.

Enrollment: 10 estimated patients

Sex: Female

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Biologic female

2. 50 years of age and older

3. Confirmed diagnosis of breast cancer:

   1. Infiltrating ductal carcinoma
   2. ER/PR+Her2neu-
   3. Grade I, II, or III

4. Unicentric, unilateral tumor size ≤ 3cm

5. Tumor location ≥ 2 cm from skin and other structures

6. Zubrod Performance Status of 0, 1, or 2

7. No palpable lymphadenopathy

8. Able and willing to provide written informed consent

Exclusion criteria

1. Pregnant or breastfeeding
2. Neoadjuvant chemotherapy
3. Cardiac arrhythmia
4. Patients with active implantable medical devices, such as implanted cardiac pacemakers or defibrillators, or any other electronic device
5. Current or history of breast implants
6. Multi-centric or bilateral breast cancer
7. Diffuse microcalcifications
8. Participating in another ongoing clinical study in which concomitant diagnostic or therapeutic intervention that would reasonably be expected to alter the outcomes under study
9. Has a condition or is in a situation which in the Investigator's opinion may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Feasibility and safety study for women undergoing BCS.

Experimental group

Description:

RFA electrosurgical device as an adjunct to BCS.

Treatment:

Device: Radiofrequency ablation Electrosurgical Device

Device: Radiofrequency ablation alone